United States District Court of Massachusetts Bars Activist 1Globe Capital and Jiaqiang Li From Making Further Materially Misleading Statements Regarding Sinovac
Effectively, the decision compels 1Globe to 'come clean' after years of deliberately circumventing proper disclosure laws to mislead other shareholders of their true ownership position and intentions regarding their investment in Sinovac. As Vivo demonstrated to Judge Myong J. Joun by a substantial likelihood, 1Globe failed to provide disclosures mandated by federal securities laws while they clandestinely formed a group with ally OrbiMed, took control of Sinovac's Board of Directors, carried out plans and proposals to weaken the corporate governance and business of Sinovac, and attempted to enrich themselves at the expense of all shareholders, including by attempting to illegally disenfranchise Vivo and certain other shareholders.
Judge Joun cited multiple examples of 1Globe's coordinated activities that formed the background of their repeated disclosure violations, including:
Mr. Li involved three relatives to discreetly build positions in Sinovac, later used to the activists' advantage in the 2018 Annual General Meeting for Shareholders ('AGM'); the relatives' stock positions and relations to Mr. Li were not publicly disclosed.
In the lead-up to the 2018 AGM, and during 1Globe's legal battle against the Company, 1Globe failed to make any Sinovac-related disclosures until after the shareholder vote occurred.
1Globe and its allies were found by both the High Court of Hong Kong and a regulator from the People's Republic of China to have forged documents on separate occasions in 2018 and 2020, respectfully, to unlawfully change the directors of Sinovac subsidiaries.
This decision affirms Vivo's efforts to restore transparent corporate governance at Sinovac. Given the precedent set by 1Globe, Vivo believes they, along with OrbiMed, will continue their attempts to harm and disenfranchise shareholders until and unless the Board is reconstituted. Vivo has remained steadfast in its mission to restore trust in the Company's governance, and ultimately, in the Company's ability to resume trading and return cash to shareholders, despite 1Globe's attempts to illegally exclude Vivo from exercising our lawful right to vote at the upcoming Special Meeting of Shareholders to be held on Wednesday, July 9, 2025 at 8:00 a.m. China Standard Time (Tuesday, July 8, 2025 at 8:00 p.m. Atlantic Standard Time).
Vivo echoes the calls by other long-term shareholders, such as SAIF Partners and Prime Success, to remove the current Board, controlled by 1Globe, and vote the GOLD card in favor of SAIF Partners' qualified candidates, and to discard the Company's white card.
If the new Board is elected, Vivo believes they will restore proper governance, a critical step to enable the Company to (i) retain a new auditor, (ii) accelerate the implementation of a legitimate, audited, and realistic dividend plan maximizing all shareholders' returns, (iii) get back on track towards restoring trading on the NASDAQ, and (iv) end all cost-consuming shareholder disputes.
About Vivo Capital
Founded in 1996, Vivo Capital is a leading global healthcare investment firm with a diverse, multi-fund investment platform spanning venture capital, growth equity, buyout, and public equities. The Firm has approximately $5.3 billion in regulatory assets under management and has invested in over 430 public and private companies globally. Headquartered in Palo Alto, California, the Vivo team consists of more than 75 multi-disciplinary professionals. Vivo invests broadly in healthcare across multiple sub-sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets globally.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
15 hours ago
- Business Upturn
Amber Enterprises board approves enabling resolution to raise up to Rs 2,500 crore
Amber Enterprises India Ltd has announced that its Board of Directors, at a meeting held on July 12, 2025, has approved an enabling resolution to raise funds of up to ₹2,500 crore. The proposed fundraising will be through the issuance of permissible securities and is subject to necessary regulatory approvals and shareholder consent. This move was disclosed in accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and follows the company's earlier intimation dated July 9. The company noted that further details regarding the type and mode of securities will be shared in compliance with SEBI's November 2024 circular, once finalized. Additionally, the Board approved the Notice of the 35th Annual General Meeting (AGM), which is scheduled to be held on Monday, August 11, 2025, at 3:00 PM IST. The AGM notice and the Annual Report for FY 2024-25 will be shared with the stock exchanges in due course. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Wire
a day ago
- Business Wire
SINOVAC Board Sets the Record Straight on July 8 Special Meeting of Shareholders
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) ('SINOVAC' or the 'Company') today issued the following update to set the record straight regarding the Special Meeting of Shareholders (the 'Special Meeting'): The Special Meeting was validly adjourned by SINOVAC Chairman Chiang Li on July 8, 2025, due to pending litigation in Antigua regarding the validity of the shares purportedly issued following an invalid private investment in public equity ('PIPE') to Advantech/Prime and Vivo Capital (together known as the 'Dissenting Investor Group'). The adjournment has been recognized by the independent Inspector of Elections who has the sole authority to announce and certify the results of the Special Meeting. SAIF's false claim that a 'continuation of the Special Meeting' occurred is intentionally deceptive and entirely illegal under the Company's bylaws and Antiguan law. Immediately after the Special Meeting was validly adjourned and the virtual meeting was terminated, a group of lawyers representing SAIF and the Dissenting Investor Group purportedly self-organized an invalid, pretend special meeting at an unannounced location and time. This group did not give advance notice to valid shareholders or give them an option to attend, and they did not contact SINOVAC Chairman Chiang Li, the only authorized chair for the Special Meeting. No inspector of elections presided over the pretend special meeting. The current SINOVAC Board understands Mr. Yuk Lam Lo attended the invalid meeting with the understanding that he had no authority to chair any such shareholder meeting. At the pretend special meeting, this group announced pretend 'voting results' from a 'vote' that did not take place due to the valid adjournment. The following day, SAIF and the Dissenting Investor Group held a pretend meeting to elect a pretend Chairman. Valid SINOVAC shareholders are admonished to ignore these theatrics. The Board, consisting of Dr. Chiang Li (Chairman), Mr. Yuk Lam Lo, Mr. Sven Borho and Mr. Geoffrey Hsu, retains full authority to run SINOVAC. None of the pretend board's rogue actions are valid or legal. SAIF and the Dissenting Investor Group will be held responsible. At the time of the Special Meeting, the injunction granted by the Eastern Caribbean Supreme Court of Antigua and Barbuda (the 'Antigua High Court') on July 7, 2025 – prohibiting the PIPE shares from voting at the meeting – had not been overturned. While the Eastern Caribbean Court of Appeal temporarily stayed the injunction order, the stay is in place until a hearing is held to determine whether such stay should have been granted. On July 11, 2025, Judge Bakre of the Antigua High Court issued a ruling, which stated that granting a stay would make a 'mockery' of this case. There are ongoing legal proceedings in Antigua to determine the validity of the PIPE shares. The current Board will reconvene the Special Meeting once this issue is resolved by the proper court. During this period, voting is unavailable. All valid shareholders will have their vote counted at the validly reconvened Special Meeting. The current SINOVAC Board remains in place, is governing the Company, and is executing on its stated priorities. These include dividend distributions according to its previously announced policy, in addition to the ongoing payment of the US$55.00 per common share special cash dividend paid to valid shareholders or their brokers beginning on July 7, 2025, working with NASDAQ to resume trading, the appointment of a new auditor, and exploring a future listing on the Stock Exchange of Hong Kong to promote liquidity and maximize value creation. The SINOVAC Board urges all shareholders to rely only on official communications from the rightful Board for accurate information. The Board remains committed to transparency and the rule of law and will provide further updates as developments occur. For ongoing updates and further information, please visit About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Important Additional Information and Where to Find It In connection with SINOVAC's Special Meeting, SINOVAC has filed with the U.S. Securities and Exchange Commission ('SEC') and mailed to shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a WHITE proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and other interested parties will be able to obtain the documents free of charge at the SEC's website, or from SINOVAC at its website: You may also obtain copies of SINOVAC's definitive proxy statement and other documents, free of charge, by contacting SINOVAC's Investor Relations Department at ir@ Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'potential,' 'continue,' 'is/are likely to' or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's or Board's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.
Yahoo
a day ago
- Yahoo
Better Fintech Stock: Block vs. SoFi Technologies
Block's two key segments are posting solid growth, and its Bitcoin-related activities could provide further benefits. SoFi is rapidly expanding its customer and revenue base, helping it grow its bottom line. 10 stocks we like better than SoFi Technologies › Investing at the intersection of financial services and technology can be a lucrative endeavor. Companies operating here, such as Block (NYSE: XYZ) and SoFi Technologies (NASDAQ: SOFI), provide critical products and services to their customers. And they're staring at tremendous growth opportunities. Both have their merits, but which of these fintech stocks is the better buy right now? Block (originally known as Square) started out selling a small credit card reader that could be attached to a smartphone, helping small merchants accept payments wherever they were. Today, the business has morphed into much more. The company's Square segment offers a wide range of products, software, and financial services that help facilitate commerce. In the first quarter, Square handled $54 billion in gross payment volume. The company also operates Cash App, a personal finance platform that can be used as a substitute for a traditional bank. Besides sending and receiving money, Cash App offers direct deposit, savings accounts, debit cards, stock trading, and Bitcoin trading. Cash App ended Q1 with 57 million monthly active users. Both Square and Cash App continue to grow their gross profits at or near double-digit percentage rates. Yet, despite the success of these two ecosystems, Block co-founder and CEO Jack Dorsey has shifted his attention more to Bitcoin, the world's leading cryptocurrency. Block has developed and now sells a Bitcoin hardware wallet. It's working on crypto mining equipment. And merchants who use Square will be able to accept payment in Bitcoin. It's all part of a strategy intended to boost adoption of the crypto. Critics won't hesitate to call this a distraction from what should be Block's main focus -- offering financial products and services to merchants and individuals. But if Bitcoin continues on its impressive trajectory, and Block finds a way to monetize its related activities, these efforts could be a boon for the business in the long run. While the massive money-center banks get most of the attention, SoFi has made a name for itself by carving out a niche in the financial services industry with a focus on innovation and disruption. It emphasizes providing its customers with an exceptional user experience, operating with no physical bank branches, and leaning heavily on technology. It's clearly working, as SoFi currently has 10.9 million customers, more than triple the number it had at the end of 2021. SoFi has done a great job of targeting a younger and more affluent demographic. This is a valuable group to cater to because they could be SoFi customers for decades, taking advantage of more of its services as their financial lives evolve. Its revenue is also soaring: It rose 20% year over year in Q1 to $772 million. SoFi makes money, unsurprisingly, from the interest it collects on student, personal, and home loans. This is an important business line. However, the company is seeing monster growth from financial services, like checking and savings accounts, credit cards, and brokerage offerings, where its revenues more than doubled year over year. Throughout most of its history, SoFi posted net losses. That's not a shock, as it was able to access cheap capital that it deployed in pursuit of rapid growth. Generating profits was not a priority. This dynamic has shifted, though, and last year, SoFi reported positive net income. The management team sees the bottom line rising rapidly in the years ahead. The past year has been wildly different for these companies' stocks. Block's share price has climbed just 4% in the past 12 months (as of July 8). Over that same period, SoFi's stock price has rocketed 211% higher. Block's business growth in the face of macroeconomic headwinds has been noteworthy. And the company has added upside potential from its Bitcoin-related endeavors. On the other hand, SoFi keeps putting up solid financial performances as its profitability improves. In my view, both of these businesses are worthy of owning, regardless of how their shares have done recently. Before you buy stock in SoFi Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and SoFi Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $694,758!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $998,376!* Now, it's worth noting Stock Advisor's total average return is 1,058% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 7, 2025 Neil Patel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bitcoin and Block. The Motley Fool has a disclosure policy. Better Fintech Stock: Block vs. SoFi Technologies was originally published by The Motley Fool Sign in to access your portfolio
